Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caroline B Madsen

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Oncoimmunology|June 5, 2013
Glycan-mediated modification of the immune responseCaroline B Madsen, Anders E Pedersen, Hans H Wandall
Immunopharmacology and Immunotoxicology|September 26, 2013
Potential for novel MUC1 glycopeptide-specific antibody in passive cancer immunotherapyCaroline B Madsen, Hans H Wandall, Anders Elm Pedersen
Transplant Immunology|July 17, 2010
Elevated mRNA levels of CTLA-4, FoxP3, and granzyme B in BAL, but not in blood, during acute rejection of lung allograftsCaroline B Madsen, Astrid Nørgaard, Martin Iversen, et al.
Immunopharmacology and Immunotoxicology|September 11, 2012
MUC4-specific CTLsCaroline B Madsen, Per Jess, Mikkel Harndahl, et al.
Transplant Immunology|August 24, 2013
The number of regulatory T cells in transbronchial lung allograft biopsies is related to FoxP3 mRNA levels in bronchoalveolar lavage fluid and to the degree of acute cellular rejectionDorrit Krustrup, Caroline B Madsen, Martin Iversen, et al.
Plos One|November 29, 2012
Cancer associated aberrant protein O-glycosylation can modify antigen processing and immune responseCaroline B Madsen, Cecilie Petersen, Kirstine Lavrsen, et al.
Plos One|September 17, 2013
Glycan elongation beyond the mucin associated Tn antigen protects tumor cells from immune-mediated killingCaroline B Madsen, Kirstine Lavrsen, Catharina Steentoft, et al.
Glycoconjugate Journal|August 11, 2012
Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicityKirstine Lavrsen, Caroline B Madsen, Morten G Rasch, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Oncoimmunology|June 5, 2013
Glycan-mediated modification of the immune responseCaroline B Madsen, Anders E Pedersen, Hans H Wandall
Immunopharmacology and Immunotoxicology|September 26, 2013
Potential for novel MUC1 glycopeptide-specific antibody in passive cancer immunotherapyCaroline B Madsen, Hans H Wandall, Anders Elm Pedersen
Transplant Immunology|July 17, 2010
Elevated mRNA levels of CTLA-4, FoxP3, and granzyme B in BAL, but not in blood, during acute rejection of lung allograftsCaroline B Madsen, Astrid Nørgaard, Martin Iversen, et al.
Immunopharmacology and Immunotoxicology|September 11, 2012
MUC4-specific CTLsCaroline B Madsen, Per Jess, Mikkel Harndahl, et al.
Transplant Immunology|August 24, 2013
The number of regulatory T cells in transbronchial lung allograft biopsies is related to FoxP3 mRNA levels in bronchoalveolar lavage fluid and to the degree of acute cellular rejectionDorrit Krustrup, Caroline B Madsen, Martin Iversen, et al.
Plos One|November 29, 2012
Cancer associated aberrant protein O-glycosylation can modify antigen processing and immune responseCaroline B Madsen, Cecilie Petersen, Kirstine Lavrsen, et al.
Plos One|September 17, 2013
Glycan elongation beyond the mucin associated Tn antigen protects tumor cells from immune-mediated killingCaroline B Madsen, Kirstine Lavrsen, Catharina Steentoft, et al.
Glycoconjugate Journal|August 11, 2012
Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicityKirstine Lavrsen, Caroline B Madsen, Morten G Rasch, et al.
Pageof 1